



Perosphere to Present Investigational Broad-Spectrum Anticoagulant Reversal Agent PER977 Data at American College of Cardiology (ACC) 64th Annual Scientific Sessions

- Sunday, March 15, 2015, 10:15 AM PT: PER977 Reverses Low Molecular Weight Heparin in Addition to IIa and Xa New Oral Anticoagulants
-

Monday, March 9, 2015

DANBURY, Conn.--(FOR IMMEDIATE RELEASE)--Perosphere Inc. will present data from studies involving the investigational broad-spectrum anticoagulant reversal agent PER977 during the American College of Cardiology (ACC) 64th Annual Scientific Sessions, March 14-16, in San Diego, CA.

PER977 Poster Presentation

- Presentation Title: PER977 Reverses Low Molecular Weight Heparin in Addition to IIa and Xa New Oral Anticoagulants
- Poster Presentation Time: Sunday, March 15, 2015, 10:15 AM – 10:30 AM Pacific Time
- Session: Moderated Poster
- Session #: 1203M
- Session Title: Advances in Management of Deep Venous Thrombosis
- Session Time: Sunday, March 15, 2015; 9:45 AM – 10:30 AM Pacific Time
- Session Location: Vascular Medicine Moderated Poster Theater, Poster Hall B1

About the Need for Anticoagulation Reversal

Anticoagulation is utilized for the treatment and prevention of thrombosis in upwards of seven million patients annually in the United States. Despite the volume of anticoagulants used, as many as half of the patients who are candidates for treatment do not receive appropriate therapy, often due to concerns by both physicians and patients regarding increased risk of hemorrhage and associate morbidity (intracranial hemorrhage, transfusion, hypovolemia, shock, compartment syndrome, cardiac arrest). An additional serious consideration among patients receiving anticoagulants is disruption of therapy in the event of emergency surgery or invasive procedures resulting in elevated risk of thrombosis in the interim.

In the United States for the 12 months ending June 2013, among patients treated with anticoagulants enoxaparin, rivaroxaban, apixaban and dabigatran, it is estimated that approximately 299,000 patients experienced bleeding with approximately 106,000 emergency room and 68,000 hospital admissions. Current therapies for the management of bleeding secondary to anticoagulation are supportive. Therefore, a single broad-spectrum reversal agent for the new oral anticoagulants (NOACs), low-molecular-weight heparin and unfractionated heparin would provide an improved therapeutic option for these serious conditions while addressing an unmet medical need.

About PER977

PER977 is a small synthetic water-soluble new molecular entity that directly combines with the NOACs (i.e., direct Xa- and IIa- inhibitors), fondaparinux, low molecular weight heparins and unfractionated heparins allowing rapid re-establishment of a normal blood coagulation state. This reversal effect is due to direct binding to the anticoagulant molecule with no binding to blood coagulation factors or to other proteins in the blood. PER977 is undergoing clinical development as a sterile, intravenous injection. Phase 2 studies are nearing completion.

About Perosphere

Perosphere is a private specialty pharmaceutical company focused on developing rescue medications. For more information, please visit www.perosphere.com.

Contacts

Solomon S. Steiner, PhD
President & CEO
Perosphere Inc.
203-885-1116
s.steiner@perosphere.com

James C. Costin, MD
EVP of Clinical & Medical Affairs, CMO
Perosphere Inc.
203-885-1369
j.costin@perosphere.com